Menu

Search

  |   Business

Menu

  |   Business

Search

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Seattle Genetics, Inc. To Contact The Firm Before Lead Plaintiff Deadline

NEW YORK, Jan. 11, 2017 -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Seattle Genetics, Inc. (“Seattle Genetics” or the “Company”) (NASDAQ:SGEN) of the March 13, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Western District of Washington on behalf of all those who purchased Seattle Genetics securities between October 27, 2016 and December 23, 2016 (the “Class Period”).  The case, Patel v. Seattle Genetics, Inc. et al, No. 2:17-cv-00041 was filed on January 10, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) the Company’s experimental cancer drug, vadastuximab talirine, presents a significant risk of fatal hepatotoxicity; (ii) Seattle Genetics had overstated the viability of vadastuximab talirine as an acute myeloid leukemia treatment; and (iii) as a result, Seattle Genetics’ public statements were materially false and misleading.

Specifically, on December 27, 2016, Seattle Genetics announced that the U.S. Food and Drug Administration had placed a clinical hold or partial clinical hold on several early stage trials of vadastuximab talirine, to evaluate the potential risk of hepatotoxicity.  The Company stated, in part, that “six patients have been identified with hepatotoxicity, including several cases of veno-occlusive disease, with four fatal events.”

After the announcement, Seattle Genetics’ share price fell from $61.86 per share on December 23, 2016 to a closing price of $52.36 on December 27, 2016—a $9.50 or a 15.36% drop.

Request more information now by clicking here: www.faruqilaw.com/SGEN. There is no cost or obligation to you.

Take Action

If you invested in Seattle Genetics stock or options between October 27, 2016 and December 23, 2016 and would like to discuss your legal rights, visit www.faruqilaw.com/SGEN. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].  Faruqi & Faruqi, LLP also encourages anyone with information regarding Seattle Genetics’ conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. 

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
[email protected]
Telephone: (877) 247-4292 or (212) 983-9330

Primary Logo

  • ET PRO
  • Market Data

Market-moving news and views, 24 hours a day >

November 24 15:30 UTC Released

USECRI Weekly Index*

Actual

145.6 %

Forecast

Previous

145.6 %

November 24 14:45 UTC Released

US1st Half-Mth Infl YY*

Actual

54.6 %

Forecast

Previous

54.6 %

November 27 09:00 UTC 36503650m

ITExport Prices*

Actual

Forecast

Previous

111 %

November 27 09:00 UTC 36503650m

ITImport Prices*

Actual

Forecast

Previous

116.1 %

November 27 14:00 UTC 39503950m

MXTrade Balance, $*

Actual

Forecast

Previous

-1.886 Bln USD

November 27 14:00 UTC 39503950m

MXTrade Balance SA*

Actual

Forecast

Previous

-1.559 Bln USD

November 27 15:30 UTC 40404040m

USDallas Fed mfg bus index

Actual

Forecast

Previous

27.6

November 27 21:00 UTC 43704370m

KRBOK Manufacturing BSI*

Actual

Forecast

Previous

87 Bln BRL

November 28 00:00 UTC 45504550m

BRCentral Govt Balance

Actual

Forecast

Previous

-22.725 Bln BRL

November 28 07:00 UTC 49704970m

DEGDP Growth QQ* Advance

Actual

Forecast

Previous

10.7 %

Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.